Extended Data Fig. 10: Expression of fast-responding inflammatory factors is elevated in psoriasis patients and the ds-cRNA treatment is beneficial in patient-derived PBMCs.
From: Therapeutic application of circular RNA aptamers in a mouse model of psoriasis
(a) The expression of circRNAs is reduced in the lesional skin samples, compared to the non-lesional skin samples. Total expression level of circRNAs from lesional and non-lesional skin samples derived from 27 psoriasis patients19,20 are analyzed. Top, total FPBcirc values of all circRNAs; median, total FPBlinear values of all circRNAs cognate linear RNAs; bottom, total CIRCscore values of all circRNAs. Wilcoxon rank-sum test, n.s., p > 0.05, ***p < 0.001. (b) Heatmap of the psoriasis-related genes of lesional and non-lesional skin in psoriasis patients. The expression level of each gene is scaled by z-score and each category is shown in the same scale bar, indicated by intervals. (c) EPIC-LNPs suppresses the expression of psoriatic signature genes in PBMCs isolated from psoriasis patients. 1 pmol of EPIC was delivered into roughly 106 cells. Each dot represents one patient sample. n.s., p > 0.05, *p < 0.05, paired student’s t test.
